指南与共识胃肠动力与功能性疾病

美国胃肠病学会-美国胃肠病学院临床实践指南:慢性特发性便秘的药物治疗

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
指南 / 共识 · Gastroenterology · 2023-01-01

美国胃肠病学会与美国胃肠病学院联合制定本指南,采用推荐分级的评估、制定与评价框架对纤维、渗透性泻药、刺激性泻药、促分泌药及5-羟色胺4受体激动剂进行系统评价,形成10条成人慢性特发性便秘药物治疗推荐。

要点

  • 强推荐聚乙二醇、匹可硫酸钠、利那洛肽、普卡那肽和普芦卡必利用于成人慢性特发性便秘。
  • 对纤维、乳果糖、番泻叶、氧化镁和鲁比前列酮给出条件性推荐。
  • 临床医生应结合患者偏好、药物费用与可及性进行共享决策。

核心结论

  • 本指南为成人慢性特发性便秘的药物治疗提供循证推荐框架。
  • 共达成10条药物治疗推荐,涵盖非处方与处方药物。

研究设计与样本

  • 美国胃肠病学会与美国胃肠病学院组建多学科指南小组。
  • 对纤维、渗透性泻药(聚乙二醇、氧化镁、乳果糖)、刺激性泻药(比沙可啶、匹可硫酸钠、番泻叶)、促分泌药(鲁比前列酮、利那洛肽、普卡那肽)及5-羟色胺4受体激动剂(普芦卡必利)进行系统评价。
  • 采用推荐分级的评估、制定与评价框架评估证据确定性,并基于证据至决策框架制定推荐。

主要发现

  • 指南小组就成人慢性特发性便秘的药物治疗达成10条推荐。
  • 基于现有证据,对聚乙二醇、匹可硫酸钠、利那洛肽、普卡那肽和普芦卡必利作出强推荐。
  • 对纤维、乳果糖、番泻叶、氧化镁和鲁比前列酮作出条件性推荐。

关键数值与推荐

  • 强推荐:聚乙二醇用于成人慢性特发性便秘。
  • 强推荐:匹可硫酸钠用于成人慢性特发性便秘。
  • 强推荐:利那洛肽用于成人慢性特发性便秘。
  • 强推荐:普卡那肽用于成人慢性特发性便秘。
  • 强推荐:普芦卡必利用于成人慢性特发性便秘。

临床怎么用

  • 指南旨在为慢性特发性便秘的管理提供框架。
  • 临床医生应基于患者偏好以及药物费用和可及性进行共享决策。
  • 文中强调证据的局限性与空白以指导未来研究方向并改善慢性便秘患者的照护。

局限性

  • 文中强调证据存在局限性与空白,以帮助指导未来研究方向并改善慢性便秘患者的照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults. METHODS: The American Gastroenterological Association and the American College of Gastroenterology formed a multidisciplinary guideline panel that conducted systematic reviews of the following agents: fiber, osmotic laxatives (polyethylene glycol, magnesium oxide, lactulose), stimulant laxatives (bisacodyl, sodium picosulfate, senna), secretagogues (lubiprostone, linaclotide, plecanatide), and serotonin type 4 agonist (prucalopride). The panel prioritized clinical questions and outcomes and used the Grading of Recommendations Assessment, Development, and Evaluation framework to assess the certainty of evidence for each intervention. The Evidence to Decision framework was used to develop clinical recommendations based on the balance between the desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 10 recommendations for the pharmacological management of CIC in adults. Based on available evidence, the panel made strong recommendations for the use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride for CIC in adults. Conditional recommendations were made for the use of fiber, lactulose, senna, magnesium oxide, and lubiprostone. DISCUSSION: This document provides a comprehensive outline of the various over-the-counter and prescription pharmacological agents available for the treatment of CIC. The guidelines are meant to provide a framework for approaching the management of CIC; clinical providers should engage in shared decision making based on patient preferences as well as medication cost and availability. Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023. PMID: 37211380. doi:10.1053/j.gastro.2023.03.214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。